EUR 23.6
(1.72%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 15.38 Million EUR | -1.18% |
2022 | 15.57 Million EUR | 173.66% |
2021 | 5.68 Million EUR | -39.76% |
2020 | 9.44 Million EUR | -56.07% |
2019 | 21.5 Million EUR | 25.57% |
2018 | 17.12 Million EUR | 2.47% |
2017 | 16.71 Million EUR | 2.01% |
2016 | 16.38 Million EUR | 35.56% |
2015 | 12.08 Million EUR | -78.21% |
2014 | 55.47 Million EUR | 14.88% |
2013 | 48.28 Million EUR | 9.1% |
2012 | 44.25 Million EUR | 89.29% |
2011 | 23.38 Million EUR | 38.99% |
2010 | 16.82 Million EUR | 79.89% |
2009 | 9.35 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 18.17 Million EUR | 0.0% |
2023 Q4 | 15.38 Million EUR | 0.0% |
2023 Q2 | 14.8 Million EUR | 0.0% |
2023 FY | 15.38 Million EUR | -1.18% |
2022 Q2 | 5.11 Million EUR | 0.0% |
2022 Q4 | 15.57 Million EUR | 0.0% |
2022 FY | 15.57 Million EUR | 173.66% |
2021 Q4 | 5.68 Million EUR | 0.0% |
2021 Q2 | 6.53 Million EUR | 0.0% |
2021 FY | 5.68 Million EUR | -39.76% |
2020 Q2 | 14.34 Million EUR | 0.0% |
2020 FY | 9.44 Million EUR | -56.07% |
2020 Q4 | 9.44 Million EUR | 0.0% |
2019 FY | 21.5 Million EUR | 25.57% |
2019 Q4 | 21.5 Million EUR | 0.0% |
2019 Q2 | 25.13 Million EUR | 0.0% |
2018 Q4 | 17.12 Million EUR | 0.0% |
2018 FY | 17.12 Million EUR | 2.47% |
2018 Q2 | 17.42 Million EUR | 0.0% |
2017 Q4 | 16.71 Million EUR | 0.0% |
2017 Q2 | 21.56 Million EUR | 0.0% |
2017 FY | 16.71 Million EUR | 2.01% |
2016 FY | 16.38 Million EUR | 35.56% |
2016 Q2 | 11.82 Million EUR | 0.0% |
2016 Q4 | 16.38 Million EUR | 0.0% |
2015 Q4 | 12.08 Million EUR | 0.0% |
2015 FY | 12.08 Million EUR | -78.21% |
2015 Q2 | 83.99 Million EUR | 0.0% |
2014 Q4 | 55.47 Million EUR | 0.0% |
2014 FY | 55.47 Million EUR | 14.88% |
2014 Q2 | 57.25 Million EUR | 0.0% |
2013 Q4 | 48.28 Million EUR | 0.0% |
2013 FY | 48.28 Million EUR | 9.1% |
2013 Q2 | 50.63 Million EUR | 0.0% |
2012 Q3 | 44.25 Million EUR | -6.13% |
2012 Q1 | 47.14 Million EUR | 101.64% |
2012 FY | 44.25 Million EUR | 89.29% |
2012 Q2 | 47.14 Million EUR | 0.0% |
2012 Q4 | 44.25 Million EUR | 0.0% |
2011 FY | 23.38 Million EUR | 38.99% |
2011 Q4 | 23.38 Million EUR | 0.0% |
2011 Q2 | 22.12 Million EUR | 0.0% |
2010 Q4 | 16.82 Million EUR | 0.0% |
2010 FY | 16.82 Million EUR | 79.89% |
2009 FY | 9.35 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Apontis Pharma AG | 27.2 Million EUR | 43.432% |
Dermapharm Holding SE | 1.62 Billion EUR | 99.054% |
Evotec SE | 1.17 Billion EUR | 98.695% |
MERCK Kommanditgesellschaft auf Aktien | 22.36 Billion EUR | 99.931% |
PharmaSGP Holding SE | 91.54 Million EUR | 83.192% |
SynBiotic SE | 19.59 Million EUR | 21.461% |